The IMAGINE Center offers its users an infrastructure for data archiving and integration in BIDS format, characterized by a comprehensive architecture that covers all stages of data management and analysis. This facilitates the rapid creation of a secure, anonymous, robust, and interoperable archiving system with other data sets and treatment tools, making data quickly and easily accessible to users through data processing pipelines.

The IMAGINE Center is dedicated to developing data harmonization protocols to foster open data sharing and invigorate pediatric neuroimaging science. This platform promotes data coordination internally and across different sites through specialized IT infrastructure, allowing for seamless application of open source data processing piplines to the data that are collected on Centre IMAGINE equipment. Our infrastructure is designed with multisite collaborations in mind. Datasets will be harmonized and interoperable with other big data initiatives in child brain health.

Thanks to our team’s expertise in advanced modeling of multimodal longitudinal data, the IMAGINE Center aims to create and develop a pre- and post-treatment data analysis platform to derive normative pediatric brain maps and models of growth from one year to the next. The applied scripts and pipelines will be made available to the scientific community for this purpose.

In support of the existing genomic platforms at CHU Sainte-Justine and integrating with them, this scientific platform seeks to accelerate genetic and neuroimaging protocols and analyses in clinical trials. The Centre endeavors to build a multisite reference of quantitative longitudinal multimodal MRI data, spanning from birth to adolescence, offering unparalled opportunities for research projects on rare pediatric populations or studies evaluating treatments that require case controls. Through the harmonization of measures, highly specialized advice and training, the Centre also aims to establish a framework for the collection of basic neurobehavioral and genetic data for all patients receiving treatment for a rare genetic condition, complex neurological development issues, concussions, or early psychiatric conditions, to further identify additional biomarkers and proximal indicators of positive treatment responses.